Business UpdateJun 2, 2026, 07:41 AM
Firefly Neuroscience identifies novel PTSD biomarker with DoW link
AI Summary
Firefly Neuroscience, Inc. announced the identification of a novel electrophysiological biomarker for Post-Traumatic Stress Disorder (PTSD) using brain scans collected on its FDA-510(k)-cleared Evoke System. This discovery stems partly from Firefly's partnership with the U.S. Department of War (DoW) and leverages NVIDIA L40S GPU-accelerated infrastructure. The company believes this positions it uniquely with both a government brain health partnership and an identified neural signal marker for PTSD, potentially opening commercial pathways in defense health, pharma, and clinical psychiatry.
Key Highlights
- Identified novel electrophysiological biomarker for Post-Traumatic Stress Disorder (PTSD) using its Evoke System.
- Discovery leverages FDA-510(k)-cleared Evoke System and NVIDIA L40S GPU-accelerated infrastructure.
- Biomarker discovery emanates from Firefly's public-private partnership with the U.S. Department of War (DoW).
- PTSD affects approximately 13 million Americans annually, with an estimated U.S. economic burden of $232.2 billion.
- Potential commercial pathways include expanding the DoW partnership, use in pharmaceutical clinical trials, and clinical psychiatry.
- Firefly's proprietary database now consists of over 200,000 EEG/ERP brain scans.
Price Impact
More from AIFF